According to Novartis Group, the results of the 12th batch of centralized procurement of nationally organized drugs were announced today. Novartis cubatorvalsartan sodium tablets were successfully selected in this centralized procurement. As one of the important innovative treatment options in the cardiovascular field, sacubatl valsartan tablets have been widely used in China, providing patients with more diverse treatment options. According to the information currently available, the selection in this collection involved heart failure indications of this product.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.